Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Centre, a national research platform led by Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...

Study reveals the Prospector calculator reduces antibiotic prescriptions in COPD exacerbations, improving outcomes and ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

“Emphysema makes it hard to breathe air out of your lungs as it affects the tiny air sacs at the end of the airways where ...